Skip to main content
BBNX logo

BBNX · Beta Bionics, Inc.

Track BBNX — free
$13.36 +0.04 (+0.30%) At close · Nov 20
Market Cap
$726.34M
Shares
54.37M
Volume · Nov 20 960.33K Avg daily vol (3M) 1.21M

Price & Indicators

 

Key stats

Close
$13.36
Fri 20 Nov
Open
$13.05
Fri 20 Nov
Average volume, 30 days
1.2M
shares a session
Short interest
5.0M
9.2% of shares · 3.9 days to cover
Day range
$12.92$13.85
Open $13.05 Close $13.36
52-week closing range
$8.86$31.99
Close $13.36 58.2% under the high
Short volume, last session
55%
Last earnings
Oct 27, 2026
Latest filing
10-Q · Oct 27
Price history
Jan 2025 to Nov 2026

Up next

Feb 16, 2027 Est · unconfirmed · in 12 wks
call held Apr 21, 2026

Latest documents

2026
Oct 27
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net sales reach $35.5 million; Mint launch set for 2027

Beta Bionics reported net sales of $35.5 million for the three months ended September 30, 2026, compared to $27.3 million a year earlier. The net loss for that period was $24,353 thousand, versus $14,209 thousand. Mint patch pump received FDA clearance on September 14, 2026, with full U.S. commercial launch expected in the first quarter of 2027.

Revenue $35.51M ▲ 30.3% Net loss $24.35M Diluted EPS -$0.52
Read from the MD&A section
4 source passages
Net sales for the three months ended September 30, 2026 were $35.5 million, compared to $27.3 million for the three months ended September 30, 2025. | Net loss | (24,353) | (14,209) | (10,144) | | 71 | % | On September 14, 2026, we announced FDA clearance of Mint, our patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading CGMs and enables smartphone control for iOS and Android users. We expect to initiate the full commercial launch of Mint in the United States in the first quarter of 2027 Open the document at this passage
Oct 27
Current report 8-K
Third-quarter net sales rise 30% to $35.5 million; full-year revenue guidance raised

Beta Bionics reported third-quarter 2026 net sales of $35.5 million, up 30% from $27.3 million a year earlier, with a net loss of $24.4 million. The company raised its low-end full-year 2026 revenue guidance to $124 million to $126 million from $121 million to $126 million, noting a potential deferral of up to $8.5 million in the fourth quarter as prospective users may await Mint. It also withdrew its 3D Intelligence 510(k) application and plans to resubmit it in mid-Q4 2026.

Financial results
6 source passages
Net sales of $35.5 million, up 30% compared to $27.3 million in the third quarter of 2025. Net loss of $24.4 million, or negative 69% of sales, compared to $14.2 million or negative 52% of sales in the third quarter of 2025. Estimated total revenue of approximately $124 million to $126 million (previously $121 million to $126 million). Revenue guidance reflects a potential revenue deferral impact of up to $8.5 million in the fourth quarter of 2026 as new prospective iLet users could choose to await the launch of Mint. Following recent interactions with the U.S. Food and Drug Administration (FDA), the Company has withdrawn its 510(k) application for 3D Intelligence. The company intends to submit this revised 510(k) in mid-Q4 2026. Open the document at this passage
Sep 17
Current report 8-K Events of Sep 15
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$127.27M
Trailing 12 months
Net income (TTM)
−$83.12M
Trailing 12 months
Revenue growth YoY
+30.3%
Year over year
Operating margin
-72.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-9.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$240.20M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.7%
Year over year · more shares
Price change (1Y)
-53.0%
Trailing year
Short interest
9.2%
Latest settlement · 3.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −26%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 19%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −30%
trailing
6-month return +4%
trailing
YTD return −56%
this year
Relative strength +14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $18 › 200d $15 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +34 funds added
Insider flow Distributing
Net -$736.5K over 90 days · 100% sells
Short interest Falling
9.16% of shares out · ▼ -28.0% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
154 holders — mid 2-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Strong
Revenue growth +54%
Y/Y
Gross margin 55%
expanding
EPS growth +79%
Y/Y
Free cash flow $-56.2M
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −72%
past year
ATR 11.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 27, 2026
2026 Full Year Guidance (year ending December 31, 2026)
Estimated total revenue Lowered $124M – $126M
Jul 29, 2026 $131M – $136M changed to Oct 27, 2026 $124M – $126M
prior FY $100.25M midpoint +24.7% Y/Y
2026 Full Year Guidance
Estimated 37% to 39% of new patient starts reimbursed through th Maintained 37% – 39%
Jul 29, 2026 37% – 39% changed to Oct 27, 2026 37% – 39%
Estimated gross margin Maintained 58.5% – 59.5%
Jul 29, 2026 58.5% – 59.5% changed to Oct 27, 2026 58.5% – 59.5%
Previous outlook earlier release · from the Earnings Call filed Apr 21, 2026

Still-open targets the latest release did not restate under the same label.

Pharmacy mix (percentage of new patient starts reimbursed throug · full year 2026 37% – 39%
Prior guidance period ended · from the 8-K filed Jan 8, 2026
Net sales · fourth quarter of 2025 at least $32M
Durable Medical Equipment (DME) channel net sales · fourth quarter of 2025 at least $22.3M
Pharmacy Benefit Plan (PBP) channel net sales · fourth quarter of 2025 at least $9.7M
Percentage of new patient starts from multiple daily injections · fourth quarter of 2025 69%
Guided vs delivered · last 1 settled
Estimated total revenue full year 2025
guided at least $96.5M
$100.25M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
19% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $18 › 200d $15 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +34 funds added
Insider flow Distributing
Net -$736.5K over 90 days · 100% sells
Short interest Falling
9.16% of shares out · ▼ -28.0% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
154 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $9 Now $13 · 19% Range high $32
vs 200-day avg -10% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Durable Medical Equipment (DME) channel net sales $20.4M second quarter of 2026 —
Net sales generated through the DME channel 64% the three months ended June 30, 2026 filing —
Net sales generated through the PBP channel 36% the three months ended June 30, 2026 filing —
Pharmacy Benefit Plan (PBP) channel net sales $11.6M second quarter of 2026 —
single-use products accounted for net sales 60% the three months ended June 30, 2026 filing —
Total DME channel 20.41M the three months ended June 30, 2026 filing —
Total PBP channel 11.6M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BBNX
Beta Bionics, Inc.
this stock
$726.34M -56.2% +53.9% — 9.2%
ABT
Abbott Laboratories
$178.39B -17.8% +5.7% 38.4 1.1%
MDT
Medtronic plc
$127.84B +4.0% +8.4% 24.6 1.8%
SYK
Stryker Corp
$118.01B -11.8% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$60.85B -56.0% +12.5% 17.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
154
% held
103.8%
Net QoQ
+8.5M sh
Top holder
PRICE T ROWE ASSOCIATES I…
Held Float
View
Held by Funds
Fund positions
121
View
Short & Settlement
Short Interest Falling
Shares short
5.0M
Days to cover
3.9d
Change
-1.9M sh
View
Short Volume
Short vol %
55%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
3.3K
Value
$58.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
38.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$736.5K
Buyers / Sellers
0 / 5
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$100.3M
Net income (FY)
$-73.2M
EPS diluted
$-1.81
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 27, 2026
This year
18

Beta Bionics reported third-quarter 2026 net sales of $35.5 million, up 30% from $27.3 million a year earlier, with a net loss of $24.4 million. The company raised its low-end full-year 2026 revenue guidance to $124 million to $126 million from $121 million to $126 million, noting a potential deferral of up to $8.5 million in the fourth quarter as prospective users may await Mint. It also withdrew its 3D Intelligence 510(k) application and plans to resubmit it in mid-Q4 2026.

View
Proposed Sales
Value
$7.4K
Shares
451
Filed
Nov 16, 2026
View
Exempt Offerings
Offering
$101.8M
Filed
Sep 15, 2023
View
Earnings & Events
Webcasts
Last webcast
Oct 27, 2026
View
Investor Relations
Latest news
Senseonics and Beta Bionics Launc…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
BBNX -18.6% -30.3% +4.5% -20.2% -56.2%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -10.1% -21.0% +13.6% -11.5% -57.3%
Key facts CIK 1674632 CUSIP 08659B102 13F (30d) 146 filings 141 filers Visit website Investor relations